Fundraising Fox

Icon Bioscience

Sunnyvale, US · Delaware corporation · 1 known investors

Icon Bioscience develops biodegradable, sustained-release intraocular ophthalmic products using its proprietary Verisome drug delivery technology, targeting unmet needs in inflammation, glaucoma, and retinal disease treatment.

Founders & leadership

DT
David TierneyExecutive

Board

JEJoyce Erony
Joyce EronyinBoard directorManaging Partner at Amzak Health
ST
Song TojaBoard director
WW
William WhiteBoard director
MH
Michael HemricBoard director

Investors · 1

Reported raises · per SEC filings

Form D private placements

$5.3M disclosed across 1 round · 2015

$5.3MraisedDec 2015 · 18 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Joyce EronyDirector
  • David TierneyExecutive Officer, Director
  • Song TojaDirector
  • William WhiteDirector
  • Michael HemricDirector
Offering amount
$9.8M
Amount sold
$5.3M
First sale
Nov 2015
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap

Companies competing with Icon Bioscience for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does Icon Bioscience do?
Icon Bioscience develops biodegradable, sustained-release intraocular ophthalmic products using its proprietary Verisome drug delivery technology, targeting unmet needs in inflammation, glaucoma, and retinal disease treatment.
Who are Icon Bioscience's investors?
Icon Bioscience's investors include Signet Healthcare Partners.
How much funding has Icon Bioscience raised?
Icon Bioscience has disclosed $5.3M raised across 1 round.
Where is Icon Bioscience headquartered?
Icon Bioscience is headquartered in Sunnyvale, US.